Here is the thing . . . . NOTHING they do will SAVE MONEY for the common American . . . . .that money will simply be REDIRECTED INTO THE HANDS OF THE UBER RICH They are turning the Government into a big Money Laundering Scheme Rocket River
You mean funding billions to go to Mars doesn't make you happier than being able to afford healthcare, being able to afford necessities, or a living wage? Get your priorities straight.
At what point . . . How far away from the death . . . do you have to be in order to escape blame for it. If my decision kills someone . .. . .. how much space do i need to "get away with it" I pull a trigger - Murder I sell the gun to the person that pulls the trigger - Free I *GIVE* the gun to the person that pulls the trigger - Possible accomplice charges I make the gun - free Rocket River
https://www.city-journal.org/article/national-institutes-of-health-university-grants The National Institutes of Health Are Right to Slash University Bloat Washington should stop subsidizing bureaucracy in the name of science. Phillip H. Phan, Judge Glock Feb 13 2025 The National Institutes of Health (NIH) give billions of dollars in grants annually to professors and researchers to support important medical research. But in recent years, more than one-fourth of the value of these grants has gone not to researchers but to universities’ overhead costs. In response, the NIH has decided to cap these “indirect costs” at 15 percent of each grant. This seemingly bureaucratic move has prompted outrage from universities. One researcher calls it a “death sentence for academic institutions,” claiming that it “destroys the U.S. as a global leader in research” and “will devastate local economies.” To the contrary, the cap on overhead is the right move. It will reduce university administrative bloat, save taxpayers money, and improve medical research. Unlike direct costs—tied to specific research activities—indirect costs take the form of nebulous “facilities and administrative” expenses. The vagueness creates opportunities for cost padding and questionable expenditures. No cap currently exists on facilities expenditures, for example, offering universities “few, if any, incentives for controlling these costs,” the Government Accountability Office has said. Similarly, the GAO notes that the lack of a reimbursement limit for interest expenses encourages universities to borrow more and build more than they need for research. Indirect costs have also risen more rapidly than direct costs, according to the GAO. In 2023, NIH data showed that around 26 percent of its annual research funding was allocated to indirect costs—amounting to nearly $9 billion. Some American research institutions now charge indirect costs totaling over 60 percent of their grants. The current approach allows universities to build up bureaucracies that hinder, rather than help, researchers. The cap, by contrast, will help make these institutions leaner and more efficient. Institutions that no longer get huge grants for overhead will need to innovate, such as using digital trial-management platforms, which can speed up clinical trial timelines and reduce costs. The cap will also help ensure transparency and accountability in federal spending. If more funding is moved to direct costs, researchers and universities will have to document specific uses and justify them. For smaller universities, the new policy offers a chance to compete more effectively for NIH grants. They will no longer face a structural disadvantage compared with wealthier institutions that have leveraged high indirect costs to build up their scientific capital and laboratories. More grants to smaller institutions will grow the number of trial sites and improve access to clinical trials for populations previously left behind, especially in rural areas. This will help ensure medical research is available to all. Most importantly, the NIH’s new emphasis on efficiency and transparency will strengthen public trust in research. As more taxpayer dollars get channeled toward real research outcomes, public confidence in federally funded research could grow. That could attract new sources of private investment to complement NIH funding and ensure that public officials remain committed to funding research. A federal judge has blocked the NIH’s proposal in some states, and the NIH will need to clarify some specifics. Nevertheless, the Institutes’ decision to cap indirect costs is bold and necessary. It will help reform America’s often-broken research and university systems. Phillip H. Phan is the Alonzo and Virginia Decker Professor at the Johns Hopkins University Carey Business School with a joint appointment as a professor in the Department of Medicine. Judge Glock is the Manhattan Institute’s director of research.
A worsening measles outbreak has taken root in Texas, sickening two dozen and hospitalizing nine on the western edge of the state, where childhood vaccination rates have dwindled in recent years. As of Tuesday, 22 children and two adults had been infected, all of whom were unvaccinated. I feel sorry for the kids because they have no say, but any unvaccinated adult can go to hell
Just in health today - they fired 300 cancer researchers & disbanded the epidemic investigation unit. Also they proposed replacing antidepressant with forced labor camps What the **** is wrong with these ****ing idiots - @Os Trigonum this is a goddamned omnidisaster - why are you letting your party do this?
So much wrong with cutting cancer researchers. Just horrible. But at least they aren't spending a lot on tax breaks for the wealthy are they?
One good article deserves another! Any thoughts to debate or discuss @Os Trigonum ? https://statements.cornell.edu/2025/20250210-nih-cost-cuts.cfm Joint lawsuit challenging NIH indirect cost cuts Feb. 10, 2025 Dear Cornellians, Today, Cornell joined 11 other universities as a plaintiff in a lawsuit (PDF) filed by the Association of American Universities, the Association of Public and Land-grant Universities, and the American Council on Education challenging the cuts to indirect costs associated with National Institutes of Health (NIH) grants. We take this unprecedented step due to the unprecedented nature and enormous impact of this action by the NIH. For decades, the NIH has partnered with universities to fund facilities and administration costs associated with federal research. This arrangement has greatly enhanced biomedical research, led to innumerable medical advances, and created a virtuous cycle of discovery, innovation, and entrepreneurship that is the envy of the world. Such sudden and dramatic cuts imperil this extraordinarily successful partnership. While we welcome a thoughtful process of evaluation of indirect costs, if the research capabilities of America’s universities are destabilized and undermined in this way, no institutions will be capable of filling the void of discovery and innovation as a public good. We remain deeply committed to research that enhances the lives and livelihoods of people in New York state and around the world in tangible and lasting ways. We look forward to partnering with the NIH to ensure that we fulfill that mission together. A temporary restraining order issued today in a case filed by state Attorneys General means that Cornell will not immediately be affected by the NIH changes. Cornell and other university plaintiffs are proceeding with this lawsuit to ensure a long-term resolution. Thank you for your ongoing dedication to research at Cornell and its broader impact. We will keep you informed of developments as we continue to navigate this challenge together. Sincerely, Michael I. Kotlikoff Interim President Kavita Bala Provost Robert A. Harrington, M.D. Provost for Medical Affairs
By the way, @Os Trigonum - the dumb mother ****ers at the "city - journal" who are trying to put you into early retirement (59.5, remember that number!) don't really seem to understand the way the whole NIH /NSF grant thing works? You cant "reduce overhead" and have a proportionally linear amount of "less science" being done - the overhead pays for like "having a research facility" for the researchers to research in. Believe it or not, biotech research can largely not be done over zoom/outlook, you need labs etc, they need to have electricity and such. So basically cutting overhead to 15% is not just reducing by 1/3, it's basically+ the literal end of most research in the country. Just a staggeringly stupid self own to do this on a national level. And on a local level, for you!
lol https://carey.jhu.edu/faculty/faculty-directory/phillip-phan-phd Phillip Phan, PhD Alonzo and Virginia Decker Professor of Strategy and Entrepreneurship ACADEMIC AREA Management & Organization ACADEMIC AREA Innovation & Entrepreneurship ACADEMIC AREA Health AREAS OF INTEREST Health care innovation commercialization, national innovation policy, artificial intelligence, patient safety and quality 410-234-9434 EMAIL pphan@jhu.edu Personal Website CV Phillip H. Phan, Ph.D., is Alonzo and Virginia Decker Professor at the Johns Hopkins Carey Business School with joint appointment as Professor in the Department of Medicine. He is Robert Bosch Policy Fellow at the American Academy in Berlin. His academic and professional work focuses on innovations in health care that impacts patient safety and quality. He has published more than 200 peer reviewed research papers and is author/editor of 13 scholarly books. He is Deputy Editor of the International Journal for Quality in Health Care, Academic Editor of Medicine®, and Associate Editor of the Journal of Technology Transfer. He reviews for the National Academies of Sciences, Engineering and Medicine, National Institutes of Health, and the National Science Foundation. He is director of the Networking and Mentoring Core for the Johns Hopkins Artificial Intelligence Collaboratory for Aging Research, and PI of the Johns Hopkins Innovation for Substance Use Disorder (I4SUD) program, a NIDA-funded national technology commercialization training program for researchers in substance use disorders. Education Ph. D, University of Washington - Seattle BBA, Hospitality Management School of Travel Industry Management, University of Hawaii - Manoa Research Selected publications Sumner, J., Anjali Bundele, Hui Wen Lim, Phillip Phan, Mehul Motani, Amartya Mukhopadhyay (2024) Developing an Artificial Intelligence-Driven Nudge Intervention to Improve Medication Adherence: A Human-Centred Design Approach. Journal of Medical Systems 48, 3, https://doi.org/10.1007/s10916-023-02024-02. Long, Valencia, Chen Zhaojin, Du Ruochen, Chan Yiong Huak, Yik Weng Yew, Hazel H. Oon, Steven Thng, Nur Qasrina Binte Iskandar Lim, Chris Tan, Nisha Suyien Chandran, Jose M Valderas, Phillip Phan, Ellie Choi (2023) Understanding Discordant Perceptions of Disease Severity Between Physicians and Patients with Eczema and Psoriasis using Structured Equation Modeling. JAMA Dermatology. Published online. doi:10.1001/jamadermatol.2023.2008) Abadir, P.M., Chellappa, R., Choudhry, N. et al. (2023) The promise of AI and technology to improve quality of life and care for older adults. Nature Aging. Published online. https://doi.org/10.1038/s43587-023-00430-0 Lee, Soo-Hoon, Clarice Wee, Phillip H. Phan, Yanika Kowitlawakul, Chee Keat Tan, Amartya Mukhopadhyay (2023). Readiness for transfer: a mixed-methods study on ICU transfers of care. BMJ Open, 13(5): e064492 Runyon, Jonathan N., Eric Su, Phillip H. Phan, Thao Nguyen, Alvaro Coronado Munoz (2023) Resource Utilization and Clinical Outcomes in Severe Pediatric Traumatic Brain Injury in Texas. Critical Care Medicine, 51(1): 116 Long, Valencia, Xer Min Nicole Lau, Clara Xinyi Ng, Phillip H. Phan, Ci En Ellie Choi (2023) Discordance in perception of disease severity between patient and physicians. European Journal of Internal Medicine, 109:138-140 Phan, Phillip H., Cybele L. Abad (2022) The future of AI in health-care quality: defining the challenges and opportunities moving forward. International Journal of Quality in Health Care, 34(4): mzac080 Lee, Soo-Hoon, Tinglong Dai, Phillip H Phan, Nehama Moran, Jerry Stonemetz (2022) The Association Between Timing of Elective Surgery Scheduling and Operating Theater Utilization: A Cross-Sectional Retrospective Study, Anesthesia & Analgesia, 134(3): 455-462 Teaching Current Innovation for Humanity, Ecuador Innovation for Humanity, Lithuania Entrepreneurial Ventures Design Lab Commercializing Discoveries Previous Research and Policy Seminars in Health Social Innovation and Business Sustainability Corporate Strategy Innovation for Humanity Discovery to Market Networked Organizations Honors and distinctions SmartState® Center for Innovation + Commercialization, University of South Carolina, Advisory Panel Haniel-Stiftungsgastprofessur, Wirtschaftswissenschaftliche Fakultät, Humbolt-Universität zu Berlin (2004) Associate Editor, Journal of Business Venturing (2001-2015) Associate Editor, Journal of Financial Stability (2003-2019) Robert Bosch Foundation Public Policy Fellow, The American Academy in Berlin (2007) Tommie Goh Distinguished Visiting Professor, Singapore Management University (2008) Associate Editor, Journal of Technology Transfer (2011-) Associate Editor, Journal of Family Business Strategy (2014-2020) Editor-in-Chief, Academy of Management Perspectives (2014-) Academic Editor, Medicine® (health services research) (2014-) STaRs Visiting Professor, University of Bergamo, Italy (2019) Impact and engagement Business Director and Principal Investigator, Johns Hopkins Innovation for Substance Use Disorder Program, Johns Hopkins Medicine, and Johns Hopkins Carey Business School Director, Networking and Mentoring Core, Johns Hopkins Artificial Intelligence Technology Collaboratory for Aging Research, Johns Hopkins Malone Center for Engineering in Healthcare and Johns Hopkins Medicine Co-founder of: P4 Microbiome Inc., developer of antimicrobials for the gastrointestinal tract Pistevo LLC, developer of AI solutions to improve medical billing accuracy FKP Consulting LLC, consultancy devoted to vascular and interventional radiology. Community Mentor, A-Level Capital Editor, eix.org (Entrepreneurship and Innovation Exchange) In the media Phillip Phan, and Joe Grogan "Patients Deserve Immediate Access to FDA-Approved Innovations — Not Bureaucratic Restrictions" The Hill, May 21, 2022 Should Billionaires Exist? Radio Times (Nov 19, 2019) WHYY Public Radio Philadelphia Business leadership professors size up Washington Redskins' problems (Nov 23, 2019) WTOP 103.5 FM in Washington D.C.
His resume relevant to Medical field is quite modest, his expertise to Business and Health care management is dime a dozen worthy . My professor at McGill is still in disbelief we reached this point , this is his work (proudly worked on 2 of it) https://pubmed.ncbi.nlm.nih.gov/?term=panasci l&page=2
my sister in law is a radiologist who graduated from JH,like every institution, the hardest part to get accepted, from that point it get much easier ( more job titles than physical office spaces, I have no clue what they do exactly). I got an approval for my sabbatical leave in summer of 2026 , my proposal is about "Diet& meditation " , so I don't even work while on vacation or waste tax payers money
Ebola outbreak suspected in NYC today https://nypost.com/2025/02/16/us-ne...urgent-care-as-hazmat-crews-on-scene-sources/ But RFK jr, Musk & the DOGE neo Nazis disbanded the CDC Epidemic intelligence service on Friday night These guys are out to murder you & your family. Remember that.
I guess the reason is that they don't have to listen to him which is why they're suing Trump/doge, because NIH cuts are an existential threat to Johns Hopkins and he's just some **** head from the business school. https://president.jhu.edu/messages/2025/02/10/our-essential-research-partnership-with-the-nih/ We could point to any number of examples of how these dramatic cuts will impact our research and patient care mission, but let us offer just one: NIH funding supports approximately 600 current and ongoing clinical trials at Johns Hopkins. This includes open clinical trials in cancer, pediatrics and children’s health, heart and vascular studies, and the aging brain, among many others. The NIH funding cut endangers these trials and many more like them into the future. And these trial participants are our patients. The care, treatments, and medical breakthroughs provided to them and their families are not “overhead” – they offer meaningful hope and scientific expertise, often when it’s needed most. They are the lifeblood of the advanced care that draws patients from across the country and around the world to Johns Hopkins. Many of them come to us with life threatening conditions or diseases that have failed to respond to treatment elsewhere. They come to us because of our commitment to connecting our research with the very best clinical care. Anyway typical dumb loser **** from @Os Trigonum - can't defend ****, just copy pastas a blog. That's as deep as it gets. Tell me when you did your own publications back in the day - was this the level of care you used? I know white privilege is a thing but I didn't think it went that far!
